Xenon Pharmaceuticals Reports $90.9 Million Net Loss in Q3 2025

Xenon Pharmaceuticals Inc. reported significant financial results for the third quarter of 2025, revealing a net loss of $90.9 million, compared to a loss of $62.8 million in the same period of 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $240.6 million, up from $168.6 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which rose to $77.1 million for the quarter and $213.2 million for the nine-month period, reflecting ongoing clinical trials and development activities for its lead product candidate, azetukalner.

In terms of revenue, Xenon recognized $7.5 million during the nine months ended September 30, 2025, stemming from a milestone payment related to its collaboration with Neurocrine Biosciences. This marks a notable increase from zero revenue in the same period last year. The company’s total assets decreased to $607.8 million as of September 30, 2025, down from $798.1 million at the end of 2024, primarily due to a reduction in cash and marketable securities, which totaled $480.1 million, compared to $635.3 million at the end of the previous fiscal year.

Operationally, Xenon is advancing its clinical development programs for azetukalner, which is being evaluated for multiple indications, including epilepsy and major depressive disorder. The company is currently conducting several Phase 3 clinical trials, with patient enrollment ongoing. The increase in research and development expenses is largely driven by costs associated with these trials, as well as the expansion of its workforce to support late-stage development efforts. As of September 30, 2025, the company had 77.1 million common shares outstanding, reflecting a slight increase from the previous quarter.

Looking ahead, Xenon anticipates continued significant operating losses as it invests in the development of azetukalner and other product candidates. The company expects to require additional funding to support its operations and development activities, as it has not yet generated substantial revenue from product sales. Management indicated that the existing cash and marketable securities are expected to fund operations for at least the next 12 months, but the company remains dependent on future capital raises and collaboration agreements to sustain its growth and development initiatives.